drugset / Trial / NCT03136328

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

NCT03136328

Phase 3 Completed 11 enrolled Montefiore Medical Center NCM USA · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.

Timeline

Start
2016-05-16
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATOC Peptide 111 mbq Intravenous
Subject 68Ga-DOTATOC Peptide 185 mbq Intravenous